Detección de mutaciones en los genes K-ras, H-ras y EGFR en muestras de plasma sanguíneo y cepillado cervical de pacientes con neoplasia intraepitelial cervical (NIC) III y cáncer de cuello uterino by García, Dabeiba Adriana et al.
43
Colombia Médica                        Vol. 40 Nº 1, 2009 (Enero-Marzo)
Detection of genes mutations in the K-ras, H-ras and EGFR in samples of
blood plasma and cervical smears for patients with
cervical intraepithelial neoplasia III and cervical cancer
DABEIBA ADRIANA GARCÍA, MSC1, YAZMÍN ROCÍO ARIAS, MSC2, FABIO ANCÍZAR ARISTIZÁBAL, PHD2
SUMMARY
Introduction: Cervical cancer is the second most important cancer in women worldwide, and the second cause of cancer
death in women. It has been shown that the process of cervical carcinogenesis presents as genetic and epigenetic components
as environmental issues. At present, many studies are addressed in searching for molecular markers such as mutations in
oncogenes and/or tumor suppressor genes that are associated with the progression of this disease, the most studied candidate
genes in cervical cancer in different populations have been H-ras, K-ras, EGFR among others.
Objective: The present study identified human papilloma virus (HPV) generic and specific in DNA-free plasma and cervical
smears of invasive cervical cancer patients and patients with cervical intraepithelial neoplasia (CIN) III in addition to assessing
genetic alterations, such as mutations in the genes H-ras, EGFR and K-ras.
Methods: To do so generic HPV was detected by PCR with primers GP5+/GP6+, and specific HPV 16 and 18 in E6/E7 region;
to detect mutations in codon 12 of H-ras, codons 12 and 13 of K-ras and EGFR exon 21 was conducted by direct sequencing
of PCR products of these gene fragments.
Results: Getting a good correlation between samples of blood plasma and cervical smears for both; the findings of HPV
p=0.0374 and evaluated mutations p=0. In general, for EGFR in exon 21 mutations were not found, as for codons 12 and 13
in K-ras and codon 12 in H-ras.
Conclusion: The use of DNA in plasma may be relevant to the analysis of mutations and the presences of tumor markers
are not available from other samples.
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Detección de mutaciones en los genes K-ras, H-ras y EGFR en muestras de plasma sanguíneo y cepillado cervical de
pacientes con neoplasia intraepitelial cervical (NIC) III y cáncer de cuello uterino
RESUMEN
Introducción: El cáncer cervical es el segundo cáncer más importante en mujeres a nivel mundial y la segunda causa de
muerte en mujeres por cáncer. Se ha demostrado que el proceso de carcinogénesis cervical presenta componentes tanto
genéticos, epigenéticos y medio ambientales. En la actualidad, muchos estudios se encaminan en la búsqueda de marcadores
moleculares como mutaciones en oncogenes y/o genes tumor supresor que se asocien con la progresión de esta entidad. Los
genes candidatos más estudiados en cáncer cervical en distintas poblaciones han sido H-ras, K-ras, EGFR entre otros.
Objetivos: Se identificó el virus de papiloma humano (VPH) genérico y específico en el ADN libre de plasma y de cepillado
cervical de pacientes con cáncer cervical invasivo y con neoplasia intraepitelial cervical (NIC) III además de evaluar alteraciones
genéticas, como mutaciones en los genes H-ras, K-ras y EGFR.
Metodología: Para ello se detectó el VPH genérico mediante PCR con los iniciadores GP5+/GP6+, y específico para VPH
16 y 18 en la región E6/E7. Para detectar las mutaciones en el codón 12 de H-ras, codones 12 y 13 de K-ras y el exón 21 de EGFR
se realizó mediante secuenciación directa de los productos de PCR de estos fragmentos génicos.
Resultados: Obteniendo una buena correlación entre las muestras de plasma sanguíneo y los cepillados cervicales, tanto
para los hallazgos de VPH p=0.0374 como para las mutaciones evaluadas p=0. En general, para EGFR en el exón 21 no se
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encontraron mutaciones, al igual que para los codones 12 y
13 en K-ras y codón 12 en H-ras.
Conclusión: El uso del ADN presente en el plasma puede
ser relevante para el análisis de mutaciones y de la presencia
de marcadores tumorales cuando no se dispone de otras
muestras.
Palabras clave: Mutaciones; Cáncer cervical;
Lesión intraepitelial de alto grado;
Papilomavirus humano; H-ras; K-ras; EGFR.
Cervical cancer is one of the world most important
diseases. In Colombia, estimated incidence is 29.4 cases
per every 100,000 inhabitants1. Cervical carcinogenesis
begins with non invasive squamous lesions that progress
to low and high grade intraepithelial squamous lesions;
and eventually generate an invasive carcinoma2.
However, predicting which of them finally progress and
which will reverse is currently impossible as the entire
cellular and molecular mechanisms involved in
progression are unknown. Even more, in spite of recent
advances uncovering several routes leading to cervical
carcinogenesis, no molecular marker been closely enough
associated with progression or clinical outcome has
been identified to date.
Multiple findings provide evidence about the increased
presence of cellular and viral DNA in plasma from
cervical cancer patients3. Patients with various cancers
like colon, esophagus, breast, pancreas, head and neck
and liver present increased levels of free circulating
plasma DNA. In addition to this, many genetic (such as
amplified oncogenes, punctual mutations involving Tu-
mor Suppressor Gene, microsatellite instabilities, etc) or
epygenetic features (such as TSG methylated promoters)
resemble those detected directly in the corresponding
tumors4. So, plasma DNA from cancer patients becomes
a promising target for detecting molecular cancer
associated alterations which could be used as early
cancer markers or an ongoing relapse of the disease
after the primary treatment. In cervical cancer, mutations
in EGFR, H-ras and K-ras, are some of the most
frequent genetic changes studied.
H-ras (Harvey) and K-ras (Kirsten) are located on
chromosomes 11 and 12 respectively. These oncogenes
code a 21 kDa protein called p21 which exhibits GTPase
activity and is implied in cell cycle regulation5. Constitutive
activation of them is mainly caused by punctual mutations
at codons 12, 13 and 61, leading to the inhibition of its
GTPase activity. High levels of ras function have been
demonstrated in lung, bladder, breast, colon and cervical
cancer among others. Besides, such mutations can be
found in normal looking tissue and pre neoplastic lesions
from cervical cancer patients, suggesting an important
role in carcinogenesis6.
EGFR (ErbB1) codes for a 170 kDa membrane
receptor involved in cell proliferation. It is located in
chromosome 7 and belongs to the ErbB tyrosine kinase
family of receptors. Other members are Her2/neu
(ErbB 2), ErbB 3 and ErbB 4. Among the extracellular
ligands of EGFR are the EGF and the TGFα7. Ligand
binding induces self phosphorylation and dimerization of
the receptor with some conformational changes
associated which initiate transduction of a transforming,
anti-apoptotic, proliferative signal. In addition, mutations
at exons 18-24, known to alterate its tyrosine kinase
activity, have been found in epithelial tumors such as
those on breast and cervix7.
Since mutations in K-ras and H-ras GTPase domains
have been presented as promising progression associated
molecular markers, and so potential tools for relapse/
metastasis detection in solid tumors, we decided to
search whether mutations found in cervical scrapes
from CIN III and cervical cancer patients in genes these
loci are accurately resembled by alterations in free
circulating plasma DNA from themselves. Presence of
HPV was also evaluated in both samples.
MATERIALS AND METHODS
Patients and sampling procedure. This is a
descriptive, crossectional study involving patients
conveniently chosen during a 6 months lapse at a third
level hospital in Bogotá DC. A cervical scrape and a
peripheral blood sample were obtained from 26 patients
who had been diagnosed with either a high grade
intraepithelial lesion (HSIL) or cervical cancer (CC),
during confirmative colposcopy. All of the patients were
fully informed and required to sign a written consent
before being enrolled in the study. None of them had
received any therapy at the time of sampling.
When obtained, every sample obtained by cervical
scrape was introduced into a tube with Timerosal 0.05%
in PBS. The tubes were kept on ice until their arrival to
lab for processing. Each blood sample was drained into
an EDTA added Venoject® tubes by venopuncture.
45
Colombia Médica                        Vol. 40 Nº 1, 2009 (Enero-Marzo)
Upon arrival, each cell suspension was centrifuged
at 3000 g for 10 minutes, then the supernatant was
discarded and de pellet was suspended in 1 ml of 10 mM
Tris-HCl buffer (pH 8.3) and boiled during 10 minutes.
After a one minute 3,000 g centrifugation the supernatant
was directly used as PCR template source. Blood
samples were centrifuged 20 minutes at 3,000 g, the
upper plasma face was separated and further centrifuged
at 8000 g for 3 minutes to completely deplete cellular
debris. DNA extraction was carried out with the
QIAamp® DNA Mini Kit (QIAGEN; Germany)
following manufactures instructions. DNA isolates were
then subjected to a pre-PCR «restoration» treatment as
previously described8. Briefly, each plasma DNA sample
is incubated at 55°C with dNTPs 200 μM for 1 hour. The
treatment is performed in the presence of Tris-HCl 10
mM, 50 mM KCl, 0.1% triton X-100, and MgCl2 3 mM.
Then one unit of Taq DNA polymerase is added an
incubated 20 minutes more at 72°C.
DNA quality. Since DNA in plasma is subjected to
multiple degradative conditions it is necessary to that
DNA extracted is quality enough to support PCR.
Quality of the DNA from cervical scrapes and plasma
(restored and non restored) was evaluated by ampli-
fication of the β-globin gene (HHB) with primers PCO3
(ACACAACTGTGTTCACTAGC) and PCO4 (CAA
CTTCATCCACCTTCACC) with Tris-HCl 10 mM, 50
mM KCl, 0.1% triton X-100, MgCl2 3 mM, 7.5 pmol
each primer, 1U Taq DNA pol and 200 μM each dNTP.
Reactions were performed in a MyCyclerTM termocycler
(BioRad Laboratorios, USA) by running the following
cycling program: 95°C - 3 minutes, and 95°C - 20
seconds, 58°C - 20 seconds and 72°C - 20 seconds for
40 repetitions. Products were analyzed by 2% agarose
electrophoresis where expected product is 110 bp long.
Lymphocyte DNA was used as positive control.
HPV detection and typification. Generic detection
of HPV was also performed by PCR with primers GP5+
(TTTGTTACTGTGGTAGATACTA) and GP6+
(GAAAAATAAACTGTAAATCATA). Reagent
conditions were as follows: Tris-HCl 10mM, 50 mM
KCl, 0.1% triton X-100, 3 mM MgCl2, 0.3 μM each
primer, 1U Taq DNA pol and 200 uM each dNTP; with
the following program: 95°C - 4 minutes; and 95°C - 1
minute, 47°C - 1 minute and 72°C - 1.5 minutes for 40
repetitions. Products were equally analyzed by electro-
phoresis as described above. DNA isolates from both
cervical scrape and restored plasma DNA from HPV
positive cases were further assayed for HPV16 and 18
by PCR targeted to the E6/E7 region. Primers used
were as follows: HPV16, primers ATCATCAAG
AACACGTAGAG and GATCAGTTGTCTCTGGTT
GCAAAT; HPV18, primers GATTTCACAACATA
GCTGGG and TGCCTTAGGTCCATGCATAC. In
both cases the first is the sense primer while the second
is the antisense primer. Reagent conditions were identical
to those for generic HPV detection, while cycling
conditions were: 94°C - 2 minutes; 94°C - 30 seconds,
60°C - 30 seconds y 72°C - 30 seconds. As before,
products were analyzed by agarose electrophoresis.
Final reaction volumes were 50 μl for generic detection
and 25 μl for type specific detection. For all HPV
detections plasmids pBR322 Zur Hausen donation
containing either HPV16 or HPV18 complete genomes
were used as positive controls.
H-ras, K-ras and EGFR mutation analysis. PCR
products were also generated to verify base identities at
codon 12 of H-ras, codons 12 and 13 of K-ras, and exon
21 of EGFR from cervical scrapes and restored plasma
DNAs. Primers used are showed in Table 1. Reagent
Table 1
Primer sequence and expected product length for H-ras, K-ras and EGFR amplicons
Gene      Primers                   Products
H-ras5 5’ GAGACCCTGTAGGAGGACCC 3’ (S)
5’ GGGTGCTGAGACGAGGGACT 3’ (A) 151 pb
K-ras5 5’ ACTGAATATAAACTTGTGGTAGTTGGACCT 3’ (S)
5’ TCAAAGAATGGTCCTGGACC 3’ (A) 357 pb
EGFR20 5’ TGATCTGTCCCTCACAGCAG 3’ (S)
5’ TCAGGAAAATGCTGGCTGAC 3’ (A) 231 pb
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conditions were as used in assays above, and a final
volume of 25 μl was used. Cycling conditions were: an
initial 94°C - 5 min denaturation step for all the amplicons;
94°C - 30 sec, 60°C - 30 sec and 72°C - 30 sec for H-
ras and K-ras; while 94°C - 30 sec, 58°C - 30 sec and
72°C - 30 sec was used for EGFR. Products were
purified with the Wizard® DNA Clean-Up System
(Promega) according to manufacturer instructions, and
sequenced in an ABI 3730 XL sequencer (Applied
Biosystems, Foster City, CA) by McLabs in San Fran-
cisco CA.
Ethical issues. This study was respected the ethic
and legal aspects for in humans research stipulated in
Resolution 008430 of 1993 (Colombian Ministry of
Health), and the 2004 modified Helsinki declaration
(1975). The patients enrolled in this study voluntarily
accepted to participate after reading and understanding
the consent form. This form was approved by the Ethics
committees of the Javeriana and National Universities
(Bogotá).
Statistical analysis. A data base was constructed
with patient’s information in an EXCEL file (Microsoft).
A one variable descriptive analysis was performed with
qualitative variables like the presence of HPV and the
presence of mutations in the sequences. Frequency
distribution was determined for each one, and association
tests were applied (Pearson’s χ2) to link cervical scrape
and plasma DNA isolates.
RESULTS
HHB (β-globin) amplification confirmed that DNA
isolates from cervical scrapes and plasma were quality
enough to generate reliable and reproducible PCR
amplifications. Besides, the pre-PCR restoration
treatment demonstrated to improve template quality,
allowing a more sensitive detection of this single copy
gene (Figure 1). In gel measurement of the band relative
optical density (ROD), shows a great increase for HHB
amplification upon plasma DNA restoration. Initial ave-
rage ROD was 427.2 while the same parameter raised
to 1032.2 after the treatment. Measures showed 286.3
and 183.4 as standard deviation respectively.
100% of cervical scrapes and 84.6% of plasmas
were positive for HPV, generic detection targets the L1
region of viral genome coding for the viral capsomer.
The stretch amplified is a 142 bp long amplicon (Table
2). Detection of this amplicon in cervical scrapes and
plasma showed great correlation as verified by a P value
of 0.0374.
Table 2
Generic HPV detection rates in cervical scrapes and restored plasma DNA isolates
from patients with CIN III and invasive cervical cancer
      Diagnosis Frequency  HPV
  plasma       scrape
CIN III 3 1 3
Invasive CC 23 21 23
Total 26 22 26
Table 3
Typification of HPV subtypes (16/18) based on cervical scrape analysis from CIN III and invasive CC
              Diagnosis                   Frequency                                 Cervical scrape
                                                                             VPH 16                    VPH 18
CIN III 3 3 0
Invasive CC 23 13 3
Total 26 16 3
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Figure 1. a. β-globin gene (HHB) amplification on plasma DNA isolates extracted with a commercial Kit
(see text). The upper row shows the amplification results on none restored plasma DNA samples, while
the lower row shows results obtained on the same samples after being restored. Lines 1-5, amplicons from
plasma samples; lines 6 and 7, positive and negative controls respectively. b. β-globin gene (HHB)
amplification on cervical scrape DNA isolates. Lines 1-5, amplicons from cervical DNA isolates; lines 6 and
7, positive and negative controls respectively.
Specific subtype detection in cervical scrapes revealed
61.5% and 11.5% of incidence for HPV16 and 18
respectively among HPV positive cases (Table 3).
Table 4
Typification of HPV subtypes (16/18) based on
restored plasma DNA isolates from
CIN III and invasive CC
Diagnosis      Frequency            Plasma
                                                VPH 16  VPH 18
 CIN III 3 1 0
 CC invasive 23 12 3
 Total 26 13 3
HPV16 was demonstrated in 50% of the plasmas while
HPV18 was detected in 11.5% of them (Table 4). In
two patients, who presented both cervical cancer and a
CIN III lesion at colposcopy, subtype specific HPV
detection was not possible. In general, though HPV16
detection in cervical scrapes was not fully matched to
that in plasmas, results demonstrate concordance (61.4%
and 50% respectively). No plasma sample showed a
HPV subtype not found in the corresponding cervical
scrape. On the other hand, HPV18 showed equal
incidence in scrapes and plasmas (11.5%).
 K-ras, H-ras and EGFR were successfully amplified
in both cervical scrapes and plasma DNA from all the
cases (Figure 2). Isoform A of EGFR was the sequence
found in all the patients. Exon 1 was shown not to be
a
b
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altered in any of the cases. Codon 12 of H-Ras didn’t
show mutations either; however, two patients showed a
third base change at codon 27 (CAT changed to CAC)
detected in both cervical scrape and matched plasma
DNA. Since it is a silent mutation, it continues to code
for Histidine. Besides, no mutations were seen in codons
12 and 13 of K-ras; however, all the patients showed a
CCT sequence in codon 11 which codes for Proline,
instead of GCT corresponding to Alanine as occurs in
the type sequence. Even though both amino acids are
non polar, they greatly differ in the contribution they do
to higher order protein holding (Figure 3).
DISCUSSION
Both genomic and viral DNA can be
effectively retrieved from plasma from CIN
III and invasive CC patients, confirming
plasma analysis as an important tool for
diagnosis and prognosis3. However, this
material could have suffered single and
double strand breakage reducing its quality
as PCR template. The restoration treatment
applied to plasma DNA isolates allows










Figure 2.a. K-ras, H-ras and EGFR
amplification on restored plasma
DNA samples. b. K-ras, H-ras and
EGFR amplification on cervical
scrapes DNA samples.
single strand gaps to be filled by using the information of
the complementary strand as template, so improving its
quality for genetic markers detection. Since the pre-
PCR restoration treatment used here does not includes
the repetitive synthesis cycles proper of PCR it does not
increases the number of copies of the target sequence.
The treatment only restores available copies so that
primers find them more efficiently8.
Regarding HPV detection in cervical scrapes, it was
100% incident among the cases analyzed; this is compa-
tible with the very high association commonly found and
Figure 3. Electrofluorograms of genes K-ras (codon 11) and H-ras (codon 27)
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supports the causal relationship between HPV and
cervical neoplasia9. HPV detection in plasma from CIN
III and CC patients allowed to classify 84.6% of the
cases as positive, which demonstrate a better detection
rate than that presented previously studies by Wei et al.4
and Widschwendter et al.10 where HPV was confirmed
in 64.7% and 45% of plasmas from patients with positive
detection in tumor respectively. Our better detection
rate can be explained by better template integrity after
the restoration treatment applied.
HPV16 was detected in 61.54% of cases (cervical
scrape detection), resembling previous studies by Rabelo-
Santos et al.11  in Brazil (57.1%); on the other hand,
HPV18 was found in 11.5% of our cases, similarly to
detection rates presented by Bosch et al.12 and Muñoz13,
whose detection rates were 14% and 13.6% respectively.
Specific detection in plasma allowed HPV16 detection
in 50% of cases, while HPV18 was found in 11.5% of
them. Previous data from assays targeted to plasma
indicate a very low rate even for generic detection.
Specific detection and typification have been conse-
quently very limited. As an example, results presented
by Dong3 were 3.5% for subtype 16 and 2.1% for
HPV18.
EGFR gene was found unaltered at exon 21 in all our
cases. Similar results are reported by Pühringer-
Oppermann et al.14 for esophageal cancer. Sequence
mutations in codon 12 of H-ras were not found in our
cases either resembling reports by Mammas et al.5 in
cervical cancer, and Vachtenheim et al.15 for lung
squamous carcinomas; however, two of the cases
showed a mutation at codon 27 (CAT to CAC) both in
scrapes and matched plasmas. Similar results are
presented by Lev et al.16 in melanoma cells.
K-ras, was not found mutated at codons 12 and 13
either, as reported by Pochylski and Kwasniewska17 in
cervical squamous cell carcinomas. However, codon 11
was found to be changed from GCT to CCT (Ala to Pro)
in all the cases. This mutation was previously found by
Gu et al.18 and Hongyo et al.19 in patients with lung
carcinomas and gastric adenomas respectively. In ge-
neral, a good correlation was observed between
sequences of H-ras, K-ras and EGFR found in cervical
scrapes and plasmas. As also demonstrated by Dong, et
al.3, sequence alterations at specific loci found in
plasma DNA isolates from cancer patients closely
resemble those present in tumors.
We conclude that analyzing free circulating DNA in
plasma from cancer patients is a reliable approximation
to tumor genetic features, allowing the analysis of
numerous genetic markers when obtaining tumor mass
samples is not an option.
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